Like has been said already. Shareholders can move on if they don't wish to own stock in the new men's health company but will still own the bryostatin CNS platform which will initialize the coming AD trial in moderate AD patients near term as the PR pointed out. Personally I would prefer a more synergistic relationship in such a merger but I always knew buying a distressed asset was a possibility. For the first time we'll be owning a revenue stream as a shareholder in the merger. Whether or not the new funds for them can expand their sales significantly remains to be seen. I can honestly say I have no opinion on that and have done no DD whatsoever. Alkon is staying on to lead the bryostatin platform and Ryan can kiss my rump. Never impressed with the guy but hope he does well with the new entity. Perhaps information will start to flow again leading up to the AD Summit in July. We can only hope. JMHO
Market Data 
Markets 
AI
